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Does offering an incentive payment improve
recruitment to clinical trials and increase the
proportion of socially deprived and elderly
participants?
Claudine G Jennings1*, Thomas M MacDonald1, Li Wei2, Morris J Brown3, Lewis McConnachie1
and Isla S Mackenzie1
Abstract
Background: Patient recruitment into clinical trials is a major challenge, and the elderly, socially deprived and those
with multiple comorbidities are often underrepresented. The idea of paying patients an incentive to participate in
research is controversial, and evidence is needed to evaluate this as a recruitment strategy.
Method: In this study, we sought to assess the impact on clinical trial recruitment of a £100 incentive payment and
whether the offer of this payment attracted more elderly and socially deprived patients. A total of 1,015 potential
patients for five clinical trials (SCOT, FAST and PATHWAY 1, 2 and 3) were randomised to receive either a standard
trial invitation letter or a trial invitation letter containing an incentive offer of £100. To receive payment, patients
had to attend a screening visit and consent to be screened (that is, sign a consent form). To maintain equality,
eventually all patients who signed a consent form were paid £100.
Results: The £100 incentive offer increased positive response to the first invitation letter from 24.7% to 31.6%, an increase
of 6.9% (P< 0.05). The incentive offer increased the number of patients signing a consent form by 5.1% (P< 0.05). The
mean age of patients who responded positively to the invitation letter was 66.5 ± 8.7 years, whereas those who responded
negatively were significantly older, with a mean age of 68.9 ± 9.0 years. The incentive offer did not influence the age of
patients responding. The incentive offer did not improve response in the most socially deprived areas, and the response
from patients in these areas was significantly lower overall.
Conclusion: A £100 incentive payment offer led to small but significant improvements in both patient response to a
clinical trial invitation letter and in the number of patients who consented to be screened. The incentive payment did not
attract elderly or more socially deprived patients.
Trial registrations: Standard care versus Celecoxib Outcome Trial (SCOT) (ClinicalTrials.gov identifier: NCT00447759).
Febuxostat versus Allopurinol Streamlined Trial (FAST) (EudraCT number: 2011-001883-23).
Prevention and Treatment of Hypertension with Algorithm Guided Therapy (British Heart Foundation funded trials)
(PATHWAY) 1: Monotherapy versus dual therapy for initiating treatment (EudraCT number: 2008-007749-29).
PATHWAY 2: Optimal treatment of drug-resistant hypertension (EudraCT number: 2008-007149-30).
PATHWAY 3: Comparison of single and combination diuretics in low-renin hypertension (EudraCT number:
2009-010068-41).
Keywords: Clinical trial recruitment, Incentive payment, Patient demographics
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Background
Efficient recruitment of patients into clinical trials is a
major challenge in medical research. Recruited patients
are often those interested in their health. The elderly, so-
cially deprived and those with significant comorbidities
are generally underrepresented. This raises concerns that
the results of clinical trials may not be generalisable to
all groups in the wider population and questions about
the validity of using outcomes from these trials when
making clinical decisions affecting the broader popula-
tion [1,2].
Various methods have been used to improve recruit-
ment into clinical trials. Recruitment strategies depend
largely on the type of trial and the patient population re-
quired. Recruitment into studies with stringent inclusion
and exclusion criteria can be particularly challenging.
Traditional recruitment methods, including use of primary
and secondary care practitioners, remain important; how-
ever, Investigators have also used public awareness cam-
paigns and advertising through various media outlets to
promote the benefits to society of participating in research
and to attract a wider variety of patients [3-5].
The concept of using financial incentives to recruit pa-
tients into clinical trials is controversial, and attitudes
toward them vary between countries and cultures. In the
United Kingdom, healthy volunteers participating in re-
search may be paid for their services [6]. For patients
participating in clinical trials, there is agreement that
they should be reimbursed for reasonable expenses;
however, there is a clear distinction between appropriate
reimbursement and additional payment as a financial
incentive to participate. The situation is different in the
United States, which has a largely insurance-based
health care system. There, financial incentives are fre-
quently used. A 2002 report found that in 32 US health
care organisations surveyed, 58% of patients were paid
an incentive to participate in research [7]. Researchers in
the United States found that moderate incentive pay-
ments were effective at improving recruitment and were
not seen as undue or unjust inducements [8].
Before further debate on the ethics of offering incen-
tive payments to patients to participate in research, we
felt it important to assess the effectiveness of incentive
payments as a recruitment strategy in Scotland, both in
terms of absolute numbers recruited and in terms of
widening the demographic profile of those screened.
Methods
We received ethical approval from the Scotland Research
Ethics Committee (REC 12/SS/0006) to assess whether
the offer of a fixed payment of £100 would improve re-
cruitment into five different clinical trials currently run-
ning in the United Kingdom. The trials studied were the
Standard care versus Celecoxib Outcome Trial (SCOT)
[9], the Febuxostat versus Allopurinol Streamlined Trial
(FAST) and the three British Heart Foundation–funded
Prevention and Treatment of Hypertension with Algo-
rithm Guided Therapy (PATHWAY) studies (1, 2 and 3).
All trial participants provided us their written, informed
consent to participate. Further details of the trials are
shown in Table 1.
For each of the five trials, potentially suitable patients
were identified through a search of their general practi-
tioners’ (GPs’) practice databases and invited to a screen-
ing visit. The invitation letters contained either the offer of
the £100 incentive payment if the patient consented to be
screened or a standard invitation letter with no incentive
offer. If there was no response to the first invitation letter,
a further letter was sent offering the incentive.
Table 1 Overview of the five clinical trials used in this studya
Trial Sponsor Outline
SCOT [10] (ClinicalTrials.gov identifier: NCT00447759) University of Dundee Trial comparing the cardiovascular safety of celecoxib with
that of other traditional NSAIDs in patients older than 60
years of age who are taking long-term NSAIDs for arthritis
FAST (EudraCT number: 2011-001883-23) University of Dundee Trial comparing the cardiovascular safety of febuxostat
versus allopurinol in patients over the age of 60 years
with symptomatic hyperuricaemia
PATHWAY 1 (EudraCT number: 2008-007749-29) University of Cambridge Trial of newly diagnosed hypertension in patients aged
18 to 79 years comparing monotherapy with dual therapy
as initial hypertension treatment
PATHWAY 2 (EudraCT number: 2008-007149-30) University of Cambridge Trial investigating treatment of resistant hypertension in
patients aged 18 to 79 years with uncontrolled blood
pressure on three anti-hypertensive agents
PATHWAY 3 (EudraCT number: 2009-010068-41) University of Cambridge Trial comparing single-agent and combination diuretic
therapy for low-renin hypertension in patients aged 18
to 80 years with at least one component of the metabolic
syndrome
aFAST, Febuxostat versus Allopurinol Streamlined Trial; NSAID, Non-steroidal anti-inflammatory drug; PATHWAY, Prevention and Treatment of Hypertension with
Algorithm Guided Therapy, British Heart Foundation–funded trials; SCOT, Standard care versus Celecoxib Outcome Trial.
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Sample size calculations were based on previous re-
cruitment rates calculated from available data and dif-
fered between the five trials. For the FAST and SCOT
studies combined, to detect a 50% increase in response
to invitation letters at 80% power required 225 letters to
be sent for each group. For the three PATHWAY stud-
ies, to detect a 50% increase would require 424 letters in
each group; therefore, for practicality, it was decided to
calculate for a 100% increase in response at 80% power,
which required 121 invitation letters to be sent for each
group. Owing to the difficulties in determining what
would be considered a worthwhile increase in recruit-
ment balanced against the cost of the incentive payment,
sample size calculations were pragmatic.
To receive the payment, the patient had to attend a
screening visit and consent to be screened for the trial (that
is, sign a consent form). To maintain equity, the £100 in-
centive was paid to all patients who signed a consent form
for any of the studies (without regard to whether the incen-
tive offer was in the invitation letter). Eligible patients who
wished to receive the payment provided bank details to the
finance department of the Medicines Monitoring Unit of
the University of Dundee, and the £100 payment was
transferred directly into the patient’s bank account after
the signed consent form was received.
Patients were randomised centrally from the Medicines
Monitoring Unit of the University of Dundee. A list of
suitable patients from each GP practice was generated by
the research nurses for each trial. Patients on this list were
randomly assigned a 0 (no incentive offer) or a 1 (incentive
offer) using a computer algorithm (rand.nextdouble() >
0.500). This was a simple fixed randomisation method ra-
ther than an adaptive method; therefore, no effort was
made to balance the groups. The code used generated ran-
dom figures from ≥0 to <1. Figures ≤0.5 were assigned a 0,
and figures >0.5 were assigned a 1. This led to a small un-
foreseen bias towards generating a 0 (no incentive offer).
This imbalance was not evident until after the trial had
been completed. Research nurses and study personnel
were not blinded to the randomisation. Allocation of the
incentive offer was independent for each trial.
Basic demographic information was recorded for each
patient who was sent an invitation letter, including age,
sex and postcode. The Scottish Index of Multiple
Deprivation (SIMD) 2012 based on postcode was used
as a measure of socioeconomic status [11]. The SIMD
combines 38 indicators across 7 domains, including in-
come, employment, health, education, skills, housing,
access and crime. Although SIMD is not a perfect indi-
cator, it was considered a reasonable way of estimating
socioeconomic status for our trial populations, given
the data we had available.
The primary outcome for this study was patient re-
sponse to the first invitation letter, depending on whether
the patient was offered the £100 incentive. Secondary out-
comes included a comparison of the demographics of pa-
tients who responded positively between the incentive and
non-incentive groups and the number of patients in each
group who consented to be screened (and therefore re-
ceived the incentive payment) and eventually were rando-
mised into each study. The response to the follow-up
letter was analysed separately. A study schematic with pa-
tient numbers is shown in Figure 1.
Data were summarised as mean and standard devi-
ation for continuous variables and number of patients
(percent) for categorical variables. The χ2 test and an in-
dependent t-test were performed to determine signifi-
cant differences. Response rates to the first invitation
letter were compared between the patients who were of-
fered the incentive and patients who were not offered
the incentive. A logistic regression model was employed
to access factors affecting positive responses to the first
invitation letter. Analysis was undertaken using SAS ver-
sion 9.2 software (SAS Institute, Cary, NC, USA).
Results
A total of 1,015 patients were sent a first invitation letter
for one of the five clinical trials. This total comprised
332 (32.7%) patients for FAST, 181 (17.8%) patients for
SCOT, 93 (9.2%) patients for PATHWAY 1, 210 (20.7%)
patients for PATHWAY 2 and 199 (19.6%) patients for
PATHWAY 3. A total of 481 (47.4%) patients were of-
fered the incentive in the first invitation letter. The mean
age of invited study subjects was 66.3 ± 9.9 years, and
58% of the patients were male. All patients were re-
cruited in the East of Scotland (Dundee, Fife and Perth).
There were no differences in age, sex, social deprivation,
geographic location and invitation to different trials be-
tween the incentive and non-incentive groups (Table 2).
Primary outcome: response to first invitation letter
The response rates to the first invitation letter were 284
(28.0%) positive responses, 279 (27.5%) negative re-
sponses and 452 (44.5%) patients who did not respond
at all. Table 3 shows the differences in positive responses
between the incentive and non-incentive groups for each
trial. Overall figures show there was a 6.9% increase in
positive responses with the incentive offer (95% confi-
dence interval (CI), 1.35 to 12.40; P = 0.04); however,
there were marked differences in response rates for each
of the five trials.
A logistic regression model based on age, sex, incen-
tive payment, trial, deprivation decile and geographic
area showed that the incentive payment, age and invita-
tion to the PATHWAY trials were significantly associ-
ated with response rates. Older patients and those
invited to the PATHWAY trials were more likely to an-
swer negatively to the first invitation letter (adjusted
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odds ratio, 0.95 (95% CI, 0.93 to 0.97) for age; 0.16 (0.07
to 0.39) for PATHWAY 1; 0.26 (0.14 to 0.50) for PATH-
WAY 2 and 0.29 (0.15 to 0.56) for PATHWAY 3).
Secondary outcomes
Patient demographics
The mean ages in years for the positive, negative and
no-response groups for all trials are shown in Figure 2.
Older patients were significantly more likely to respond
negatively to the invitation letter, regardless of whether
they were offered the incentive (P < 0.05). There are limi-
tations in combining all trials for age, as the FAST and
SCOT trials recruited only patients over the age of 60,
whereas the PATHWAY trials were open to patients as
young as 18 years of age. The oldest patients were in the
FAST trial, with a mean age of 71.5 ± 7.6 years, and the
youngest patients were in the PATHWAY 1 study, with
a mean age of 57.9 ± 11.9 years. However, within each
trial, older patients were numerically more likely to re-
spond negatively to the first invitation letter; this
reached statistical significance for the FAST, PATHWAY
1 and PATHWAY 3 studies. None of the trials showed
that the offer of the incentive affected the age of the pa-
tients responding. Full results for the effect of age on re-
sponses by trial are shown in Additional file 1: Table S1.
Patients from more deprived areas (SIMD deciles 1–3)
were less likely to respond positively to the invitation let-
ter, with an overall positive response rate of 21.3% com-
pared to an overall positive response of 31.4% from
patients in the least deprived areas (SIMD deciles 8–10)
(P = 0.032). There were no significant differences in posi-
tive response to the first invitation letter with or without
the incentive offer in the most deprived areas or in the
least deprived areas; however, patients in SIMD deciles
4–7 were significantly more likely to respond positively
to the incentive offer (37.2% versus 24.0%) (P = 0.004).
Full results are available in Additional file 2: Table S3.
Patients consented and randomised
In total, 284 patients responded positively to the first in-
vitation letter, and 184 (64.8%) of these signed a consent
form (making them eligible for the incentive payment).
Of these 184 patients, 100 who signed a consent form
were offered the incentive, which represents a 5.1%
Figure 1 Study schematic. GP, General practitioner practice; FAST, Febuxostat versus Allopurinol Streamlined Trial; PATHWAY, Prevention and
Treatment of Hypertension with Algorithm Guided Therapy, British Heart Foundation–funded trials; SCOT, Standard care versus Celecoxib Outcome Trial.
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increase in consented patients who received the incen-
tive offer (P = 0.037). Of the 184 consented patients, 167
were ultimately randomised into a trial. Table 3 shows
the differences in consented and randomised patients by
trial. The greatest (although not statistically significant)
positive changes with the incentive offer were seen in
the FAST trial.
Response to non-responder letters
Non-responder letters were sent to 374 of the 452 non-
responders to the first letter (full results are available in
Additional file 3: Table S3). The non-responder letter
contained the offer of the £100 incentive; therefore, all
non-responders were offered the incentive. The non-
responder letters generated a further 66 responses
(17.4%), of which 32 (8.6%) were positive responses;
among the latter group of 32 patients, 18 patients signed
a consent form and 14 were randomised into a trial. The
overall response rate (both positive and negative) for the
first invitation letter and the follow-up letter for the
1,015 patients contacted in this trial was 62%.
Overall outcomes for all patients
Final figures for both the first and the non-responder let-
ters show that, in total, there were 316 patients who
responded positively to the invitation letter (184 offered
the incentive, 132 not offered the incentive). Of these 316
patients, 251 attended a screening visit. A total of 202 pa-
tients signed a consent form and were eligible for the
£100. Ultimately, 181 patients were randomised into a
study (104 for FAST, 58 for SCOT, 5 for PATHWAY 1, 9
for PATHWAY 2 and 5 for PATHWAY 3). Thus, after
writing to 1,015 patients, 181 were ultimately randomised
into a trial, giving an overall randomisation rate of 17.8%.
Cost-effectiveness
The additional cost incurred in undertaking this incen-
tive payment trial was £100 per patient who signed a
consent form, as invitation letters, trial information and
screening visits were unchanged from the usual recruit-
ment process of each trial. With 202 patients consented
into the trials, the total cost of the payments to patients
in the trial was £19,900 (3 patients did not accept the in-
centive payment).
The cost to each trial of paying a £100 incentive is de-
termined by the number of patients signing the consent
form (as only these patients are paid). Some patients
who responded positively to the invitation letter did not
meet trial inclusion criteria, however; therefore, despite
their wish to participate and claim the £100, they were
ineligible. Table 4 shows the cost for each additional pa-
tient who responded positively to the invitation letter, as
well as the cost for each consenting patient if the incen-
tive was offered. Overall, the cost was £1.549 to get one
additional patient to respond positively; however, signifi-
cant differences between the trials were again evident.
Discussion
Over one-third of the patients invited to participate in a
clinical trial did not respond at all to the invitation letter.
This lack of response is commonplace when attempting
to recruit participants for research and means effective
clinical trial recruitment is difficult.
The offer of a £100 incentive payment did have some
impact in improving patient response to the first invita-
tion letter, and positive responses increased by 6.9% in
the incentive group. The improvement in initial positive
response did lead to a small (5.1%) increase in the num-
ber of patients signing a consent form. These increases
were statistically significant when looking at only the re-
sponse to the first invitation letter, but they became
non-significant when overall figures for both the first
and non-responder letters were used, owing to the poor
response to the non-responder letters.
The five trials included in this study targeted different
patient populations and required different levels of input
Table 2 Patient characteristicsa
Offered incentive
(N = 481)
Not offered
incentive (N = 534)
Age (mean, SD) 66.2 (10.2) 66.3 (9.6)
Sex
Male 281 (58.4) 308 (57.7)
Female 162 (33.7) 182 (34.1)
Unknown 38 (7.9) 44 (8.2)
SIMD deprivation categoryb
1–3 (least deprived) 138 (28.7) 134 (25.1)
4–7 242 (50.3) 274 (51.4)
8–10 (most deprived) 101 (21.0) 125 (23.5)
Geographic areasb
Angus and Dundee 217 (45.1) 215 (40.3)
Fife 200 (41.6) 234 (43.9)
Perth 64 (13.3) 84 (15.8)
Target patient group
FAST 158 (32.9) 174 (32.6)
SCOT 84 (17.5) 97 (18.2)
PATHWAY 1 46 (9.6) 47 (8.8)
PATHWAY 2 101 (21.0) 109 (20.4)
PATHWAY 3 92 (19.1) 107 (20.0)
aFAST, Febuxostat versus Allopurinol Streamlined Trial; PATHWAY, Prevention
and Treatment of Hypertension with Algorithm Guided Therapy, British Heart
Foundation–funded trials; SCOT, Standard care versus Celecoxib Outcome Trial;
SIMD, SD, Standard deviation; Scottish Index of Multiple Deprivation. Data are
mean (SD) or number (%). There were no significant differences between
groups bIncludes one patient with missing data.
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Table 3 Invitation to screening visit and outcome of first invitation letter, by triala
FAST
(N = 332)
SCOT
(N = 181)
PATHWAY 1
(N = 93)
PATHWAY 2
(N = 210)
PATHWAY 3
(N = 199)
Overall
(N = 1,015)
Offered incentive payment, n (%) 158 (47.6%) 84 (46.4%) 46 (49.5%) 101 (48.1%) 92 (46.2%) 481 (47.4%)
Not offered incentive payment, n (%) 174 (52.4%) 97 (53.6%) 47 (50.5%) 109 (51.9%) 107 (53.8%) 534 (52.6%)
Number of responses to first invitation letter Positive
Incentive offer 68 (43.0%) 34 (40.5%) 5 (10.9%) 19 (18.8%) 26 (28.3%) 152 (31.6%)
No incentive offer 54 (31.0%) 31 (32.0%) 7 (14.9%) 19 (17.4%) 21 (19.6%) 132 (24.7%)
% change with Incentive ((95% CI)) 12.0% 8.5% −4.0% 1.4% 8.7% 6.9%* (1.35 to 12.40)
Negative
Incentive offer 40 (25.3%) 15 (17.9%) 14 (30.4%) 30 (29.7%) 23 (25.0%) 122 (25.4%)
No incentive offer 49 (28.2%) 16 (16.5%) 16 (34.0%) 37 (33.9%) 39 (36.4%) 157 (29.4%)
% change with incentive ((95% CI)) −2.9% −1.4% −3.6% −4.2 −11.4% −4.0% (−1.47 to 9.47)
No response
Incentive offer 50 (31.6%) 35 (41.7%) 27 (58.7%) 52 (51.5%) 43 (46.7%) 207 (43.0%)
No incentive offer 71 (40.8%) 50 (51.5%) 24 (51.1%) 53 (48.6%) 47 (43.9%) 245 (45.8%)
% change with incentive ((95% CI)) −9.2% −9.8% 7.6% 2.9% 2.8% −2.8% (−3.27 to 8.92)
Number of patients signing a consent form Incentive offer 58 (36.7%) 26 (30.9%) 3 (6.5%) 4 (4.0%) 9 (9.8%) 100 (20.8%)
No incentive offer 41 (23.6%) 24 (24.7%) 4 (8.5%) 9 (8.3%) 6 (5.6%) 84 (15.7%)
% change with incentive ((95% CI)) 13.1% 6.2% −2.0% −4.3% 4.2% 5.1%* (0.31 to 9.85)
Number of patients randomised into trial Incentive offer 58 (36.7%) 26 (30.9%) 2 (4.3%) 3 (3.0%) 5 (5.4%) 94 (19.5%)
No incentive offer 40 (23.0%) 24 (24.7%) 3 (6.4%) 6 (5.5%) 0 73 (13.7%)
% change with incentive ((95% CI)) 13.7% 6.2% −2.1% −2.5% 5.4%* 5.9%* (1.30 to 10.49)
aCI, Confidence interval; FAST, Febuxostat versus Allopurinol Streamlined Trial; PATHWAY, Prevention and Treatment of Hypertension with Algorithm Guided Therapy, British Heart Foundation–funded trials; SCOT,
Standard care versus Celecoxib Outcome Trial. *P < 0.05.
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from recruited patients; therefore, response rates varied
significantly between the different trials. The recruit-
ment for the SCOT and FAST trials was through GP’s
writing to patients, and participants had to be older than
60 years of age and meet other entry criteria regarding
their medication and medical history. SCOT and FAST
were streamlined trials with the aim of replicating day-
to-day clinical care; therefore, patients attended a
screening visit and were then followed up remotely, so
the burden on participants was relatively small. The
PATHWAY studies recruited patients from primary care
who were aged 18–80 years with either newly diagnosed
or partially treated hypertension. All three PATHWAY
studies involved multiple patient visits to the study
centre as well as home blood pressure monitoring. The
PATHWAY trials therefore often targeted a younger,
working patient group and required a significantly
greater investment in terms of time and effort from par-
ticipants. Overall, initial positive response rates to SCOT
and FAST invitations (both with and without the
incentive) were 37% and 36%, respectively, compared to
19% for the PATHWAY trials combined. The greatest in-
crease in patients actually randomised into a trial with
the incentive offer was seen for the FAST trial, but this
13.7% increase was not statistically significant. Subse-
quent screening and randomisation rates were also sig-
nificantly poorer for all of the PATHWAY studies, which
was due to stringent study entry criteria for blood pres-
sure as well as the greater perceived burden of multiple
study visits for the participants. Recruitment into PATH-
WAY 1 and 2 appears to have been negatively affected
by the incentive offer; however, the number of consented
patients was too small to allow meaningful interpret-
ation. Recruitment into PATHWAY 3 increased with the
incentive offer, but this still represented only 5 patients
randomised out of 199 patients contacted.
Cost-effectiveness was calculated as the cost of one
additional responding or consented patient if all patients
received £100. The FAST trial showed the greatest in-
crease in consented patients with the incentive offer;
however, even with a 13.1% increase, the cost per add-
itional patient was still high at £763. It would be beyond
the scope of most studies, particularly those lacking
commercial funding, to view this as cost-effective.
The cost-effectiveness analysis is also perhaps unfair
because the calculations were based only on the number
of patients who received the payment. Patients who did
not meet study inclusion criteria were never in a pos-
ition to be able to receive the incentive payment, even
though they had indicated a willingness to take part in a
clinical trial. Therefore, cost-effectiveness figures could
be marginally improved if investigators invited fewer un-
suitable patients to screening visits.
The results of our present study indicate that the offer
of a £100 financial incentive had only a limited impact
on improving recruitment into the five clinical trials in-
volved. This may initially appear surprising, as most
people would acknowledge that we are all driven to
some extent by the attainment of financial reward. How-
ever, in the health care setting, people are motivated to
different degrees by personal gain and altruism. In 1970,
Richard Titmuss claimed that paying people for blood
donations actually made them less likely to donate, as
the payment removed the altruistic incentive [12]. It was
then suggested that increasing the payment would be
effective; however, subsequent work has shown that
payment can reduce intrinsic motivation and that
people are often distrustful of payment offered for al-
truistic behaviour, including participation in clinical
trials [13]. There is significant individual variation in
how people respond to financial incentive and complex
reasons underpinning these decisions. What may seem
a worthwhile reward for some people may not attract
others and may even actively discourage people who
Table 4 Cost per additional responding or consented
patient from first invitation letter by triala
Increase in
positive
response
with incentive
Cost per
additional
patient
Increase in
consented
patients
with incentive
Cost per
additional
consented
patient
Overall 6.9% £1,549 5.1% £1,961
FAST 12.0% £933 13.1% £763
SCOT 8.5% £1,276 6.2% £1,613
PATHWAY 1 −4.0% N/A −2.0% N/A
PATHWAY 2 1.4% £7,243 −4.3% N/A
PATHWAY 3 8.7% £1,249 4.2% £2,381
aFAST, Febuxostat versus Allopurinol Streamlined Trial; N/A, Not applicable;
PATHWAY, Prevention and Treatment of Hypertension with Algorithm Guided
Therapy, British Heart Foundation–funded trials; SCOT, Standard care versus
Celecoxib Outcome Trial.
65
65.5
66
66.5
67
67.5
68
68.5
69
69.5
Offered Incentive Group Not Offered Incentive Group
M
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e
N=152
N=122
N=132
N=157
P=0.022
P=0.040
Positive Response Negative Response
Figure 2 Bar graph showing mean age (in years) of patients
who responded positively versus negatively to the first
invitation letter with versus without the incentive offer.
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are uncomfortable with receiving financial reward for
altruistic behaviour.
The incentive offer for this study was £100. This figure
was chosen as a compromise between reasonable com-
pensation for the degree of inconvenience caused against
an effective incentive to participate. The level of the in-
centive offered must fulfil the primary objective of in-
creasing recruitment without being seen as financial
coercion. Studies done in the United States have shown
that the level of payment does influence response. For
example, in a study in which researchers looked at en-
rolling teenagers in a smoking cessation program, the re-
sults showed that any incentive was better than no
incentive and that a $15 cash incentive improved re-
sponses compared to a $2 cash incentive and entry into
a $200 prize drawing [3,10]. Incentive payments in clin-
ical research are controversial, particularly regarding
where to draw the line between financial incentive and
financial coercion. This concern is especially relevant
when trying to recruit socially deprived and vulnerable
members of society [14].
There has also been debate over whether the size of
the payment should reflect the risk or inconvenience of
the trial and if a standard formula could be developed to
determine the amount of the incentive [15,16]. The five
trials in this study were all considered low-risk (all used
medicines within their licensed indications), and there-
fore no assessment was made of the participants’ views
of the risks involved and whether this influenced their
decision to participate. Opinions are divided on this
topic, with many people feeling that higher-risk trials
should not offer incentive payments at all [17]. Re-
searchers in the United States have looked at how pa-
tients respond to payment offers in terms of both the
level of payment and the perceived risk associated with
the trial. Halpern and colleagues conducted a study
where 126 hypertensive patients were provided with in-
formation on a series of potential trials of a new anti-
hypertensive medication. In a 3 × 3 design, the risk of
adverse events and the payment offer ($100, $1,000 or
$2,000) were varied. In 34% of patients, the level of pay-
ment significantly influenced their willingness to partici-
pate. Unsurprisingly, trials with a higher risk of side
effects and lower payment offers decreased willingness
to participate. They also found a non-significant trend
towards wealthier people being more strongly influenced
by payment, but they did not find that patients’ percep-
tions of the risks associated with the trials were altered
by the level of the payment offered [8].
Our study shows that, though there may be some case
to be made for incentive payments’ marginally improving
recruitment into some trials, there was no evidence that
the incentive payment broadened the demographics of
those participating. The incentive payment offer had no
impact on the age of those responding, and, for every trial
within the study, there was a trend towards older patients
responding negatively to the invitation letter and younger
patients not responding at all (irrespective of the incentive
offer). This may reflect younger patients having work and
family commitments that prevent their participation and
older patients having different priorities, such as increased
frailty that prevents multiple study visits and presence of
multiple comorbidities that make these patients less willing
to spend additional time with health care professionals.
In terms of social deprivation, the initial positive
response (with or without the incentive offer) from pa-
tients in the most deprived areas (SIMD deciles 1–3)
was 21.3%, which was lower than the overall trial aver-
age of 28.0%. Positive responses from patients in the
least deprived areas (SIMD deciles 8–10) were higher
than the trial average at 30.7%. Patients in the middle
deprivation deciles (SMID deciles 4–7) were the only
group to show a significant increase in positive re-
sponses associated with the incentive payment. We can
only speculate on the reasons for this. It might be that
the most deprived in society are the least engaged with
health care, whereas those who are better off would not
be enticed by a relatively small payment but take a
greater interest in their health.
There are limitations to this trial, including looking at
patient recruitment from part of eastern Scotland only.
Using five diverse clinical trials complicated interpret-
ation of the results, as recruitment varied widely be-
tween trials. There are likely to have been different
factors affecting recruitment within each trial, including
how the trial was advertised and how patients were
approached. It might have been interesting to look at
different levels of payment; however, it would be
expected that a lower figure would have made even less
impact on patient recruitment and that a higher figure
would mean the trial was not financially viable. Future
work in this area could look at incentives that are not
purely financial and are individualised to patients or
trials.
Conclusions
Both simple and complex messages emerge from this
study. Put simply, paying patients £100 did entice more
people to respond positively to an invitation letter and
did result in slightly more randomised patients, particu-
larly in the FAST trial; however, this effect was marginal.
Response rates varied a great deal between the different
trials, and, even where a significant improvement was
observed, it would be a stretch to see this as a cost-
effective recruitment method. The incentive payment
did not attract the elderly or the more socially deprived.
What motivates people to participate in clinical research
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remains elusive to the research community, and it would
appear that £100 is not sufficient motivation for most.
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